



Cite this: *Org. Biomol. Chem.*, 2025, **23**, 3097

Received 31st January 2025,  
Accepted 25th February 2025

DOI: 10.1039/d5ob00176e

rsc.li/obc

## Synthesis and stability of collagen mimetic peptides featuring $\delta$ -heteroatom-substituted prolines†

Taylor A. Gerrein,‡ Madison M. Wright,‡ Natalia Cano-Sampaio and Juan R. Del Valle \*

**We describe the first investigation of collagen mimetic peptides harboring proline surrogates with heteroatoms at the  $\delta$ -position. While dehydro- $\delta$ -azaproline and (*N*-methyl)- $\delta$ -azaproline destabilized the parent structure, replacement of the Xaa proline residue with  $\delta$ -oxaproline resulted in a faster-folding collagen mimetic peptide with equivalent thermal stability.**


The collagen family of proteins is the most abundant component of mammalian connective tissue and is composed of polyproline II (PPII) chains that assemble into a right-handed triple helix.<sup>1,2</sup> The single chains in collagen feature a repeating Gly-Xaa-Yaa tripeptide motif, where Xaa and Yaa are most often proline (Pro; P) and its post-translationally modified variant 4(*R*)-hydroxyproline (Hyp; O), respectively.<sup>3</sup> Efforts to study the impact of residue substitution on collagen stability have typically relied on collagen mimetic peptides (CMPs) composed of these tripeptide repeats. Information gleaned from decades of research using CMPs has enabled the development of biomaterials, imaging and diagnostic agents, and nanoscale assemblies with unique properties.<sup>3–7</sup> The rapidly expanding set of unnatural amino acids that can be incorporated into proteins offers continued opportunity for the design of novel functional collagen mimetics.

As the only cyclic residue among the 20 canonical amino acids, Pro plays a unique role in stabilizing the collagen triple helix. The pyrrolidine ring enforces backbone  $\phi$  and  $\psi$  constraints favoring PPII conformation while the tertiary amide it forms exhibits a reduced propensity to adopt the *trans* rotamer ( $\omega$ ) geometry required in the PPII fold.<sup>8,9</sup> These characteristics suggest that cyclic analogues of Pro with enhanced *trans* amide propensity will enhance collagen stability. Indeed, replacement of Pro (at Xaa) with pyrrolidine-substituted ana-

logues has been extensively studied, with  $\gamma$ -halo,<sup>3,10</sup>  $\gamma$ -alkoxy,<sup>3</sup>  $\gamma$ -(acyl)amino,<sup>11,12</sup>  $\gamma$ -(acyl)aza,<sup>13</sup>  $\gamma$ -thia,<sup>14</sup> and  $\alpha$ -azaprolines<sup>15</sup> each maintaining or increasing the thermal stability of CMPs in the Xaa position. Interestingly, several *N*-alkyl glycine (peptoid) residues also stabilize CMPs despite significantly increased *cis* amide rotamer propensity relative to Pro.<sup>16,17</sup> In these cases, enhanced stability was attributed to the strong PPII-promoting effect of the acyclic peptoid residues, thus reducing the entropic penalty of CMP folding and outweighing the cost of reduced *trans* rotamer bias.

Our long-standing interest in N-heteroatom-substituted peptides prompted us to investigate the impact of amide-hydroxamate and amide-hydrazide replacement within the collagen backbone.<sup>18</sup> We specifically sought to study CMPs featuring cyclic  $\delta$ -heteroatom-substituted Pro analogues that retain native-like  $\phi$  and  $\psi$  constraint as well as increased *trans* rotamer propensity (Fig. 1).

Although  $\delta$ -azaproline (aPro) was initially deemed a suitable Xaa positional probe, we previously observed that aPro-containing peptides can undergo rapid air oxidation to their



**Fig. 1** Structures of  $\delta$ -heteroatom-substituted proline surrogates, crystal structure of a CMP triple helix (pdb 3B0S), and PPII strand alignment. Proposed Pro11 substitution sites are highlighted in red.

Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA. E-mail: jdelval2@nd.edu

† Electronic supplementary information (ESI) available: Experimental procedures and characterization data for all new compounds. See DOI: <https://doi.org/10.1039/d5ob00176e>

‡ These authors contributed equally to this work.



dehydro- $\delta$ -azaproline ( $\Delta$ aPro) analogues.<sup>19</sup> Our finding that the unpuckered  $\Delta$ aPro readily adopts PPII backbone conformation led us to instead explore its incorporation into a collagen folding model. We also sought to investigate (*N*-methyl)- $\delta$ -azaproline ((Me)aPro) and  $\delta$ -oxaproline (oPro), two additional Pro surrogates incapable of undergoing air oxidation. The (Me)aPro monomer has not previously been described. Although oPro has been widely employed in protein chemical ligation<sup>20–22</sup> and is found in some biologically active peptidomimetics,<sup>23–25</sup> it has not yet been explored in a model of peptide or protein folding.

Two orthogonally-protected *N*-amino dipeptide building blocks were synthesized for the incorporation of  $\Delta$ aPro and (Me)aPro into CMPs (Scheme 1). Sidechain redox adjustment of **1** was followed by dimethyl acetal protection to afford **2** in 55% overall yield. Fmoc deprotection and electrophilic amination of the resulting primary amine with *t*-butyl-diethyl-oxaziridine tricarboxylate (TBDOT)<sup>26,27</sup> provided protected  $\alpha$ -hydrazino ester **3**. *N* $\alpha$ -Acylation with Fmoc-protected Gly acid chloride and subsequent benzyl ester hydrogenolysis then gave *N*-aminated aminodimethoxybutyric acid (aAdb) derivative **5** in 56% yield over 2 steps. Synthesis of the (Me)aPro dipeptide building block proceeded *via* methylation under Mitsunobu conditions followed by tandem deprotection and reduction in the presence of TFA and triethylsilane to give **6**. Benzyl ester hydrogenolysis afforded (Me)aPro dipeptide building block **7** in 89% yield.

The oPro residue has been synthesized previously in enantiopure form *via* an auxiliary-mediated dipolar cycloaddition route<sup>20,28</sup> and, more recently, through catalytic asymmetric conjugate addition to generate a key  $\beta$ -amino aldehyde intermediate.<sup>29,30</sup> As shown in Scheme 1, we developed a chiral pool approach toward Fmoc-oPro-OH from commercially available aspartate derivative **1**. This route commenced with side chain reduction, silyl etherification, and *N*-hydroxylation using Fukuyama's procedure<sup>31</sup> to provide intermediate **10**.


Fmoc-protection, mild silyl ether cleavage, and Mitsunobu cyclization provided protected oPro **12** in 48% yield over 3 steps. Finally, benzyl ester hydrogenolysis gave monomer **13** suitable for Fmoc SPPS.

To assess the impact of  $\Delta$ aPro, (Me)aPro, and oPro on CMP stability, we chose a parent sequence comprised of seven Gly-Pro-Hyp (GPO) repeats. This peptide features N-terminal acetylation and a C-terminal amide, and exhibits a reported melting temperature of approximately 53 °C.<sup>16,32</sup> CMPs with substitutions at position 11 (Xaa) were synthesized on Rink amide MBHA resin using standard Fmoc-based protocols and HCTU/NMM activation (Table 1).  **$\Delta$ aPro11-CMP** and **(Me)aPro11-CMP** were prepared by incorporation of dipeptide building blocks **5** and **7**, respectively. Formation of the dihydropyrazole ring of  $\Delta$ aPro occurred upon acidic deprotection and cleavage from the resin. In the case of **oPro11-CMP**, condensation with the subsequent Gly10 residue was carried out using pre-formed Fmoc-protected Gly acid chloride to ensure complete reaction with the isoxazolidine nitrogen. All peptides were purified by RP-HPLC and their identities were confirmed by HRMS.

All Pro11-substituted analogues were first analyzed by far-UV CD at pH 7.4 to compare their spectral signatures to that of the parent peptide. As shown in Fig. 2A, the CD spectra of **oPro11-CMP** and **(Me)aPro11-CMP** exhibited significant overlap, including less intense and red-shifted negative bands ( $\sim$ 203–205 nm) as well as diminished maxima ( $\sim$ 225 nm) rela-


**Table 1** Synthesized CMPs with Xaa (Pro11) substitutions

Peptide	Sequence	Yield %
<b>Pro11-CMP</b>	Ac-(GPO) <sub>3</sub> -GPO-(GPO) <sub>3</sub> -NH <sub>2</sub>	5
<b><math>\Delta</math>aPro11-CMP</b>	Ac-(GPO) <sub>3</sub> -G[ <b><math>\Delta</math>aPro</b> ]-O-(GPO) <sub>3</sub> -NH <sub>2</sub>	12
<b>(Me)aPro11-CMP</b>	Ac-(GPO) <sub>3</sub> -G[(Me)aPro]-O-(GPO) <sub>3</sub> -NH <sub>2</sub>	16
<b>oPro11-CMP</b>	Ac-(GPO) <sub>3</sub> -G[oPro]-O-(GPO) <sub>3</sub> -NH <sub>2</sub>	17



**Scheme 1** Synthesis of  $\Delta$ aPro, (Me)aPro, and oPro building blocks for SPPS.






**Fig. 2** Far UV CD spectra of (A) CMPs analyzed at 150  $\mu$ M in aq PBS (pH 7.4) and (B) PP2 octapeptides analyzed at 150  $\mu$ M in 5 mM aq  $\text{Na}_3\text{PO}_4$ , 25 mM KF (pH 7.0).

tive to **Pro11-CMP**. The spectrum of  **$\Delta$ Pro11-CMP** also showed the emergence of a new minimum at 239 nm. Although these differences might indicate a destabilized triple helix, modifications to prolyl amide bonds within PPII folds have been shown to give rise to unusual CD signatures.<sup>33–35</sup> To investigate this, we synthesized single-strand PPII model octapeptides<sup>36</sup> incorporating each of the  $\delta$ -heteroatom proline surrogates. As shown in Fig. 2B, each variant displayed a significantly altered spectral signature, with  **$\Delta$ Pro4-PP2** again showing the emergence of a new minimum band near 235 nm. These spectra are in stark contrast to the prototypical random coil signature obtained upon substitution of Pro4 for a PPII-disrupting Gly residue.<sup>37</sup> These results suggest unique chromophoric properties associated with replacement of the native tertiary amide with acyl hydrazone, hydrazide, or hydroxamate bonds in the CMP series.


Thermal denaturation was then carried out for each CMP by monitoring mean residue ellipticity (MRE) at 225 nm as a function of temperature and fitting of the data to a two-state unfolding model.<sup>38</sup> The parent peptide, **Pro11-CMP**, exhibited a clear cooperative melting transition and  $T_m$  of 53.2  $^\circ\text{C}$  (Fig. 3), in agreement with previously reported values.<sup>16,32</sup> Each of the substituted variants also showed cooperative unfolding despite lacking a clear and pronounced maximum band at the tracked wavelength. The overall changes in mean residue ellipticity for  **$\Delta$ Pro11-CMP** and **oPro11-CMP** across the



**Fig. 3** Thermal denaturation of CMPs at 150  $\mu$ M in aq PBS (pH 7.4). (A) Representative plot of MRE at 225 nm as a function of temperature determined by CD. (B) Melting temperatures ( $T_m$ ) and change in  $T_m$  ( $\Delta T_m$ ) relative to **Pro11-CMP** derived from non-linear regression.  $T_m$  values represent the mean and standard deviation from two separate experiments.

temperature range were roughly equivalent to that of **Pro11-CMP**, suggesting that these variants adopt a collagen fold. While substitution of Pro11 for (Me)aPro resulted in severe destabilization of the triple helix ( $\Delta T_m = -18.4$   $^\circ\text{C}$ ),  **$\Delta$ Pro11-CMP** exhibited only a modest reduction in thermal stability ( $\Delta T_m = -2.3$   $^\circ\text{C}$ ) relative to the parent peptide. **oPro11-CMP** exhibited the same thermal stability as **Pro11-CMP** ( $T_m = 54.0$   $^\circ\text{C}$ ).

Based on our previous results with backbone *N*-oxidized peptides, we expected that the *N*-acyl bonds formed by oPro, (Me)aPro, and  $\Delta$ Pro would exhibit increased *trans* rotamer population relative to Pro.<sup>19</sup> To determine if CMP stability trends in this series correlate with *trans* rotamer propensity, we synthesized *N*-acetyl methyl esters of each monomer and calculated *trans/cis* equilibrium constants ( $K_{t/c}$ ) on the basis of  $^1\text{H}$  NMR integrations in  $\text{D}_2\text{O}$  (Fig. 4). The *trans* propensity of the hydroxamate bond in Ac-oPro-OMe ( $K_{t/c} = 6.7$ ) was slightly higher than that of the Pro amide<sup>19</sup> ( $K_{t/c} = 4.5$ ). More dramatic increases in *trans* rotamer population were observed for Ac-(Me)aPro-OMe ( $K_{t/c} = 8.3$ ) and Ac- $\Delta$ Pro-OMe<sup>19</sup> ( $K_{t/c} = 44$ ). Despite these increases,  $\Delta$ Pro and (Me)aPro destabilized the collagen model peptide, whereas oPro was accommodated in the Xaa position without energetic penalty. These results



**Fig. 4** *Trans/cis* rotamer structures and equilibrium constants ( $K_{t/c}$ ) at 25  $^\circ\text{C}$  in  $\text{D}_2\text{O}$  (derived from  $^1\text{H}$  NMR peak integrations).

suggest that the hydrazone and *N*-methyl hydrazone moieties may engage in disruptive interactions within the triple helix or preclude the adoption of optimal  $\phi$  and  $\psi$  backbone torsions.

To further parse the factors that allow for accommodation of oPro, we synthesized a CMP variant that harbors (*O*-methyl)-*N*-hydroxyalanine at position 11 (see ESI† for details). The (Me)hAla residue serves as an isoelectronic analogue of oPro that lacks cyclic constraint of the  $\phi$  and  $\psi$  backbone torsions. As shown in Fig. 5, thermal denaturation of (Me)hAla11-CMP revealed a  $T_m$  of 48.8 °C, which was ~5 °C lower than that of oPro11-CMP and Pro11-CMP. This result demonstrates that the presence of a hydroxamate bond is not sufficient to fully maintain thermal stability and that 5-membered cyclic constraint is important for folding.

Finally, we explored how  $\delta$ -heteroatom substitution in our most stable variant affected the rate of triple helix assembly. The hydroxamate bond in oPro-CMP was expected to exhibit a lower isomerization barrier than the Pro tertiary amide due to the electron-withdrawing O $\delta$ . Since the overall rate of collagen folding is limited by prolyl *cis-trans* isomerization, we hypothesized that oPro11-CMP would refold faster than Pro11-CMP.<sup>39,40</sup> Hysteresis experiments, wherein the peptides were denatured and re-cooled while monitoring by CD (at 225 nm), suggested enhancement in the refolding rate upon Pro11  $\rightarrow$  oPro11 substitution (Fig. 6A). We then quantified the relative rates of refolding using a temperature jump experiment. After holding at 95 °C for 20 minutes the peptides were quickly reintroduced into a pre-cooled cuvette and the recovery of ellipticity monitored by CD (at 7 °C). The time required to achieve a 0.5 folded fraction ( $t_{1/2}$ ) was determined by fitting to a 3<sup>rd</sup> order kinetic model.<sup>40</sup> As shown in Fig. 6B, oPro11-CMP exhibited slightly faster refolding than Pro11-CMP (10.9 vs. 17.1 min), consistent with the hysteresis data.




Fig. 5 Representative plot of MRE at 225 nm as a function of temperature for (Me)hAla11-CMP and oPro11-CMP determined by CD (150  $\mu$ M in aq PBS at pH 7.4).  $T_m$  values represent the mean and standard deviation from 2 separate experiments (SD for (Me)hAla11-CMP was  $\pm 0.5$  °C).




Fig. 6 Refolding kinetics of Pro11-CMP and oPro11-CMP. (A) Hysteresis plots of MRE at 225 nm upon heating and re-cooling as determined by CD. (B) Plot of folded fraction as a function of time upon re-cooling. Third-order non-linear fit (black line) and time of recovery for a 0.5 folded fraction ( $t_{1/2}$ ) are indicated on each graph. Values for  $t_{1/2}$  represent the mean and standard deviation from 2 separate experiments.

## Conclusions

In summary, we explored the impact of  $\delta$ -heteroatom-substituted proline surrogates on collagen triple helix folding and stability. As part of this work, we developed syntheses of  $\Delta$ Pro, (Me)JaPro, and oPro building blocks suitable for incorporation into peptides by SPPS. Thermal denaturation studies showed that introduction of oPro at the Xaa position of a model CMP affords an analogue that is isoenergetic with the parent peptide. In contrast,  $\Delta$ Pro and (Me)JaPro substitution at Xaa led to compromised thermal stability, despite the enhanced *trans* amide rotamer propensities of these residues relative to Pro. The amide-hydroxamate substitution associated with oPro incorporation also resulted in accelerated triple helix assembly. This study lays the groundwork for further investigation of oPro as a conformational surrogate of Pro in related models of protein folding.

## Data availability

The data supporting this article have been included as part of the ESI.†

## Conflicts of interest

There are no conflicts to declare.





## Acknowledgements

This work was supported by a grant from the National Science Foundation (CHE2109008).

## References

- 1 G. N. Ramachandran and G. Kartha, *Nature*, 1954, **176**, 593–595.
- 2 P. Fratzl, *Collagen: Structure and Mechanics*, Springer, New York, NY, 2008.
- 3 M. D. Shoulders and R. T. Raines, *Annu. Rev. Biochem.*, 2009, **78**, 929–958.
- 4 J. A. Fallas, L. E. R. O'Leary and J. D. Hartgerink, *Chem. Soc. Rev.*, 2010, **39**, 3510–3527.
- 5 V. Kubyshkin, *Org. Biomol. Chem.*, 2019, **17**, 8031–8047.
- 6 S. A. H. Hulan and J. D. Hartgerink, *Biomacromolecules*, 2022, **23**, 1475–1489.
- 7 J. Xiao, *Collagen mimetic peptides and their biophysical characterization*, Springer, Singapore, Singapore, 2022nd edn, 2024.
- 8 D. E. Stewart, A. Sarkar and J. E. Wampler, *J. Mol. Biol.*, 1990, **214**, 253–260.
- 9 M. W. MacArthur and J. M. Thornton, *J. Mol. Biol.*, 1991, **218**, 397–412.
- 10 Y. Nishi, S. Uchiyama, M. Doi, Y. Nishiuchi, T. Nakazawa, T. Ohkubo and Y. Kobayashi, *Biochemistry*, 2005, **44**, 6034–6042.
- 11 R. S. Erdmann and H. Wennemers, *J. Am. Chem. Soc.*, 2012, **134**, 17117–17124.
- 12 J. Egli, C. Siebler, M. Köhler, R. Zenobi and H. Wennemers, *J. Am. Chem. Soc.*, 2019, **141**, 5607–5611.
- 13 M. R. Aronoff, J. Egli, M. Menichelli and H. Wennemers, *Angew. Chem., Int. Ed.*, 2019, **58**, 3143–3146.
- 14 T.-L. Hsu and J.-C. Horng, *Protein Sci.*, 2023, **32**, e4650.
- 15 Y. Zhang, R. M. Malamakal and D. M. Chenoweth, *Angew. Chem., Int. Ed.*, 2015, **54**, 10826–10832.
- 16 J. L. Kessler, G. Kang, Z. Qin, H. Kang, F. G. Whitby, T. E. Cheatham 3rd, C. P. Hill, Y. Li and S. M. Yu, *J. Am. Chem. Soc.*, 2021, **143**, 10910–10919.
- 17 R. Qiu, X. Li, K. Huang, W. Bai, D. Zhou, G. Li, Z. Qin and Y. Li, *Nat. Commun.*, 2023, **14**, 7571.
- 18 I. J. Angera, M. M. Wright and J. R. Del Valle, *Acc. Chem. Res.*, 2024, **57**, 1287–1297.
- 19 Y. M. Elbatrawi, K. P. Pedretty, N. Giddings, H. L. Woodcock and J. R. Del Valle, *J. Org. Chem.*, 2020, **85**, 4207–4219.
- 20 A. O. Ogunkoya, V. R. Pattabiraman and J. W. Bode, *Angew. Chem., Int. Ed.*, 2012, **51**, 9693–9697.
- 21 T. G. Wucherpennig, F. Rohrbacher, V. R. Pattabiraman and J. W. Bode, *Angew. Chem., Int. Ed.*, 2014, **53**, 12244–12247.
- 22 J. Farnung, H. Song and J. W. Bode, *Methods Mol. Biol.*, 2021, **2355**, 151–162.
- 23 A. Vasella, R. Voefray, J. Pless and R. Huguenin, *Helv. Chim. Acta*, 1983, **66**, 1241–1252.
- 24 V. Günzler, D. Brocks, S. Henke, R. Myllylä, R. Geiger and K. I. Kivirikko, *J. Biol. Chem.*, 1988, **263**, 19498–19504.
- 25 K. Abrahamsson, P. Andersson, J. Bergman, U. Bredberg, J. Brånalt, A.-C. Egnell, U. Eriksson, D. Gustafsson, K.-J. Hoffman, S. Nielsen, I. Nilsson, S. Pehrsson, M. O. Polla, T. Skjaeret, M. Strimfors, C. Wern, M. Öwegård-Halvarsson and Y. Örtengren, *MedChemComm*, 2016, **7**, 272–281.
- 26 A. Armstrong, L. H. Jones, J. D. Knight and R. D. Kelsey, *Org. Lett.*, 2005, **7**, 713–716.
- 27 B. M. Rathman, J. L. Rowe and J. R. Del Valle, *Methods Enzymol.*, 2021, **656**, 271–294.
- 28 A. Vasella and R. Voefray, *J. Chem. Soc., Chem. Commun.*, 1981, 97–98.
- 29 T. J. Harmand, C. E. Murar, H. Takano and J. W. Bode, *Org. Synth.*, 2019, 142–156.
- 30 C. E. Murar, T. J. Harmand and J. W. Bode, *Bioorg. Med. Chem.*, 2017, **25**, 4996–5001.
- 31 H. Tokuyama, T. Kuboyama, A. Amano, T. Yamashita and T. Fukuyama, *Synthesis*, 2000, 1299–1304.
- 32 T. Fiala, E. P. Barros, M.-O. Ebert, E. Ruijsenaars, S. Riniker and H. Wennemers, *J. Am. Chem. Soc.*, 2022, **144**, 18642–18649.
- 33 Z. Miao and J. P. Tam, *J. Am. Chem. Soc.*, 2000, **122**, 4253–4260.
- 34 C. Cayrou, A. Walrant, D. Ravault, K. Guitot, S. Noinville, S. Sagan, T. Brigaud, S. Gonzalez, S. Ongeri and G. Chaume, *Chem. Commun.*, 2024, **60**, 8609–8612.
- 35 R. W. Newberry, B. VanVeller and R. T. Raines, *Chem. Commun.*, 2015, **51**, 9624–9627.
- 36 A. M. Brown and N. J. Zondlo, *Biochemistry*, 2012, **51**, 5041–5051.
- 37 B. H. Rajewski, M. M. Wright, T. A. Gerrein and J. R. Del Valle, *Org. Lett.*, 2023, **25**, 4366–4370.
- 38 D. Shortle, A. K. Meeker and E. Freire, *Biochemistry*, 1988, **27**, 4761–4768.
- 39 J. M. Davis and H. P. Bächinger, *J. Biol. Chem.*, 1993, **268**, 25965–25972.
- 40 K. Mizuno, S. P. Boudko, J. Engel and H. P. Bächinger, *Biophys. J.*, 2010, **98**, 3004–3014.

